BioSpace News Archive

A quick overview of life science companies scooping up some summer spending money this week.

Biogen reportedly withdrew a paper it had submitted to the medical journal JAMA after the publication requested edits before publication. It’s standard for a technical journal to request edits, but it is the nature of the edits—and in this case, the nature of the study— that raises questions.

Amgen will gain Teneobio’s proprietary bispecific and multispecific antibody technologies, which have the potential to target multiple diseases across Amgen’s core therapeutic areas.

The extension will see a new investment of nearly $1 billion, which AbbVie and Calico will split down the middle.

The research will focus on accelerating the capacities of BLU-222, an investigational therapy that Blueprint designed to target cyclin-dependent kinase 2 (CDK2).

I-Mab announced that an IND application for the initiation of a phase 2 clinical trial of efineptakin alfa in combination with anti-PD-1 antibody in patients with advanced solid tumors, including triple-negative breast cancer and head and neck cancers, has been accepted by the Center for Drug Evaluation of the China National Medical Products Administration.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 2, 2021 at 8:30 AM ET to discuss results for the second quarter 2021 and provide a business outlook for the remainder of the year.

In association with Heart Rhythm 2021, BIOTRONIK announced that the latest implantable cardiac monitor, BIOMONITOR IIIm, has been recognized by internationally-renowned research analysts Frost & Sullivan as high-performing across a range of innovation and customer value criteria.

XOMA Corporation (NASDAQ: XOMA), announced today NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation in pancreatic cancer by the U.S. Food and Drug Administration.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming second quarter 2021 earnings call and webcast, reporting financial results for the quarter ended June 30, 2021